知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.016 秒)

    GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTS
    8.
    发明申请
    GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTS 有权

    公开(公告)号：US20210108256A1

    公开(公告)日：2021-04-15

    申请号：US17080201

    申请日：2020-10-26

    申请人： The Johns Hopkins University

    发明人： Victor E. Velculescu ,  Mark Sausen ,  Vilmos Adleff ,  Jillian A. Phallen

    IPC分类号： C12Q1/6827 ,  C12Q1/6886 ,  C12Q1/6816

    摘要： Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.

    DETECTION OF CANCER
    10.
    发明申请
    DETECTION OF CANCER 审中-公开

    公开(公告)号：US20200157636A1

    公开(公告)日：2020-05-21

    申请号：US16610772

    申请日：2018-05-03

    申请人： The Johns Hopkins University

    发明人： Victor Velculescu ,  Jillian A. Phallen

    IPC分类号： C12Q1/6886 ,  G16B30/10 ,  G16B20/20 ,  C12Q1/6806

    摘要： Provided herein are methods of detecting circulating tumor DNA, cancer cell mutations, and/or cancer cells harboring one or more cancer cell mutations. In some embodiments, methods provided herein include detecting one or more genetic alterations in cell-free DNA. In some embodiments, methods provided herein for detecting one or more genetic alterations in cell-free DNA can be performed when the subject is not known to harbor a cancer cell and/or a cancer cell mutation (e.g., when the subject is not known to harbor a cancer cell having the cancer cell mutation).